PHV25: QUALITY OF LIFE OF ADULT PATIENTS TREATED FOR A RESPIRATORY TRACT INFECTION  by Lachaine, J et al.
Abstracts 125
85% (I) and 100% (II); midecamycin, 85% in both;
ampicillin, 91% (I) and 80% (II); spiramycin, 82% (I)
and 74% (II); the efficiency of ciprofloxacin was only
67% (I) and 81% (II); erythromycin, 78% (I) and 41%
(II); gentamycin, above 40% in both; trimethoprim/sul-
famethoxazole, 46% (II). The best cost-effectiveness ratio
was calculated for ampicillin, azithromycin, medecamy-
cin in both groups. The treatment with ciprofloxacin and
co-amoxiclav was less cost-effective in group I. CON-
CLUSION: The most commonly used antibiotics for
treatment of CAP were ampicillin and macrolides. This
type of treatment is adequate from medical and economic
points of view. Using of fluoroquinolones and aminogly-
cosides should be limited by gram-negative etiology.
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Adherence with HIV antiviral regimens, particularly with
the protease inhibitor (PI) is important to achieve HIV vi-
ral suppression. Complicated, multi-drug regimens can
be difficult for patients to comply with and may affect
outcomes. OBJECTIVE: To analyze adherence rates with
3-drug HIV regimens and assess the correlation of each
regimen’s adherence to HIV RNA values. METHODS:
Medication adherence and HIV RNA levels were mea-
sured in 21 patients enrolled in clinical trials in a univer-
sity-based HIV clinic. Data were collected at baseline, 2
weeks, at 4-week intervals for 24 weeks, and 8- to 12-
week intervals thereafter for up to 96 weeks. Monthly
medication adherence was calculated using pill counts.
Plasma HIV RNA was measured by standard and ultra-
sensitive RT-PCR assay. All patients were on a PI plus
2NRTI regimen. PIs included saquinavir, indinavir, and
nelfinavir. NRTIs included AZT, d4T, 3TC, and ddI. RE-
SULTS: Patient adherence with PI therapy (86%) was
found to be significantly lower (P  0.0001) than with
NRTI1 (97.7%) and NRTI2 (100.4%). Adherence rates
between NRTI1 and NRTI2 were not significantly differ-
ent. All 3 drug adherence rates were found to be nega-
tively correlated to the log of the plasma HIV RNA level
(PI R  0.430, NRTI1 R  0.181, NRTI2 R 
0.199). However, a linear regression model found that
only PI adherence was a significant predictor of HIV
RNA levels. CONCLUSION: This study indicates that
adherence with the PI regimen was significantly lower
than with nucleoside analog compounds. The results also
indicate that only adherence with the PI was a significant
predictor of virologic response.
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Assessing the impact of HIV infection and its treatment
on patient-reported health outcomes, such as health-
related quality of life (HRQOL), is critically important.
Therefore, evidence for the validity of HRQOL instru-
ments in persons with HIV is essential in evaluating the
appropriateness of their use. OBJECTIVES: The purpose
of this study was to evaluate the ability of the SF-12’s
mental and physical component summary scores (i.e.,
PCS-12 and MCS-12) to discriminate between HIV-
infected subjects in pre-defined disease severity groups
based on clinical indicator status. METHODS: This
cross-sectional study involved the collection of clinical
data (i.e., CD4 cell counts, HIV-1 viral load) from pa-
tients’ medical records and self-completion of the SF-12
at two HIV specialty clinics. The relationships between
the following variables were examined: PCS-12 scores,
MCS-12 scores, CD4 cell counts, and plasma HIV-1 viral
load. In addition, the ability of the SF-12 summary scores
to discriminate between subjects stratified by disease se-
verity (i.e., CD4  200 vs. CD4  200; viral load 
30,000 vs. viral load  30,000) was assessed. RESULTS:
Data were collected from 478 subjects. Statistically sig-
nificant correlations were found between the PCS-12 and
CD4 cell counts (r  0.208, P  0.000) and viral loads
(r  0.131, P  0.01). There were no statistically sig-
nificant correlations found between the MCS-12 and ei-
ther of the clinical indicators. The scores from the PCS-12
were able to discriminate between groups of subjects
stratified by disease severity based on CD4 cell counts
(P  0.000) and viral loads (P  0.01). CONCLUSIONS:
These findings provide evidence that, although the SF-12
is a brief, generic health status measure, it can be a useful
means of monitoring HIV-related disease status from the
patient’s perspective.
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Although the impact of diseases and treatments on qual-
ity of life has become a major concern in the evaluation
of health care interventions, it has been seldom evaluated
for acute respiratory tract infections (RTI). OBJECTIVE:
To measure the quality of life in adults treated for com-
munity acquired RTI. METHODS: Patients aged 18
were recruited by community pharmacists. They were
considered for inclusion if they reported being treated for
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an RTI and received a new prescription for one of the fol-
lowing antibiotics: amoxicillin, amoxicillin/clavulanate,
azithromycin, cefaclor, cefuroxime, ciprofloxacin, clarithro-
mycin or erythromycin. Patients were asked to complete
a self-administered quality of life questionnaire (QLQ-
C30) on day 1, 3, 7 and 14. They were also asked to indi-
cate their perception of their health status on a rating
scale. RESULTS: Of 989 patients recruited, 777 returned
their questionnaire (79%). Scores for the global health
status scale of the QLQ-C30 were expressed on a scale of
0 to 100 where 100 corresponds to a high global health
status. Mean score was 47 (sd  24) on day 1, 60 (sd 
20) on day 3, 74 (sd  19) on day 7 and 83 (sd  17) on
day 14. Improvement from day 1 to 14 varied according
to the antibiotic prescribed (ANOVA, P  0.04), how-
ever post-hoc analysis did not reveal any pairwise signifi-
cant difference (Scheffe, P  0.05). Results from the rat-
ing scale were strongly correlated with those obtained
with the global health status scale of the quality of life
questionnaire. CONCLUSION: RTIs have a definite im-
pact on patients’ quality of life, particularly on the first
few days. Quality of life steadily improves during the
course of the treatment.
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OBJECTIVE: To ascertain whether a change in co-amox-
yclav (A/C) market share was associated with changes in
patient outcomes in otitis media, sinusitis, lower respira-
tory infection and acute exacerbation of chronic obstruc-
tive airways disease. METHODS: An integrated database
of computerised records from four general practices,
based in 3 Australian States was collated for the period
mid-1994 to mid-1998. The database consisted of
34,242 patients and 318,234 notes. Conditions of inter-
ests and identifiable patient outcomes were sought. After
identification of the change in A/C market share using
segmented regression, a time series analyses was com-
pleted to define the relationship between the A/C market
share and rate of patient outcomes per encounter. The
A/C and all antibiotic market shares, the number of epi-
sodes of care (EOC) for the chosen conditions, the antibi-
otics prescribed and the patient casemix were measured.
The patient outcomes chosen included hospitalization,
referral to a specialist, CT scan of sinus and of chest,
chest x-ray, any pathology tests, spirometry, bronchos-
copy and sinoscopy. RESULTS: In total there were
11,378 EOC for all specified problems. 1082 people had
been given A/C for at least one EOC and 5879 other anti-
biotics. The casemix profile for both groups was similar.
The total number of negative outcomes were 1873, com-
prising 126 hospitalizations, 351 referrals, 794 radiology
investigations, 561 pathology tests and 41 other investi-
gations. The time series analyses revealed that for every
1% reduction in A/C market share, there was a 0.5 % in-
crease in negative outcomes, with a three month lag. The
3-month lag was the most significant (P  0.0001). The
decrease in A/C market share was related to an increase
in weighted costs of negative outcomes (P  0.0024).
CONCLUSIONS: A statistical, temporal association was
found between a fall in A/C market share among the
study GPs and a rise in negative patient outcomes.
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OBJECTIVES: The purchase price of antibiotics is often
an overriding factor in making acquisition or formulary
decisions. However, the economic consequences of using
drugs also include the costs of treatment failure and side
effects, e.g. additional therapies, tests, procedures, spe-
cialists, and hospitalization. This study evaluated the
costs and outcomes of antibiotic therapy for febrile neu-
tropenia in 9 European countries. METHODS: A model
was developed based on data from two clinical trials
comparing either the high- or low-dose regimen of piper-
acillin/tazobactam  amikacin versus ceftazidime  ami-
kacin. Clinical trial data provided the dosage, efficacy,
mortality and days with fever. Practice pattern data, in-
cluding duration of treatment and length of stay, were
provided by 3–6 clinicians in each country. Cost informa-
tion on drugs, hospital resource use and outpatient fol-
low-up care was obtained from primary and secondary
data sources in each country. Prices were expressed in
1995 currency and converted to US dollars and Euros for
comparison. RESULTS: Piperacillin/tazobactam  ami-
kacin was more effective than ceftazidime  amikacin for
both dosage regimens, resulting in fewer first-line therapy
failures, reduced number of hospital days and lower mor-
tality. Despite slightly higher daily drug costs for the piper-
acillin/tazobactam regimen, in 17 of 18 scenarios modeled
average total treatment costs were lower for piperacillin/
tazobactam than for the ceftazidime regimens for both
the high-dose and low-dose formulations in all 9 coun-
tries. CONCLUSIONS: In the treatment of febrile neu-
tropenia, piperacillin/tazobactam  amikacin was more
effective and less costly than ceftazidime  amikacin
when total treatment costs were considered. Thus piper-
acillin/tazobactam dominates its alternative, with similar
results across all 9 countries.
